Skip to main content
SpringerLink
Log in

Treatment of Neuroendocrine Tumour Disease

  • Chapter
  • First Online:
Liver Cancers

  • 998 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010;17(4):909–18.

    Article  PubMed  Google Scholar 

  2. Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451(4):757–62.

    Article  CAS  PubMed  Google Scholar 

  3. La Rosa S, Inzani F, Vanoli A, Klersy C, Dainese L, Rindi G, et al. Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Hum Pathol. 2011;42(10):1373–84.

    Article  PubMed  Google Scholar 

  4. Burkitt MD, Pritchard DM. Review article: pathogenesis and management of gastric carcinoid tumours. Aliment Pharmacol Ther. 2006;24(9):1305–20.

    Article  CAS  PubMed  Google Scholar 

  5. Cavallaro A, Zanghì A, Cavallaro M, Menzo EL, Carlo ID, Vita MD, et al. The role of 68-Ga-DOTATOC CT-PET in surgical tactic for gastric neuroendocrine tumors treatment: our experience: a case report. Int J Surg. 2014;12:S225–31.

    Article  PubMed  Google Scholar 

  6. Thomas D, Tsolakis AV, Grozinsky-Glasberg S, Fraenkel M, Alexandraki K, Sougioultzis S, et al. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. Eur J Endocrinol. 2013;168(2):185–93.

    Article  CAS  PubMed  Google Scholar 

  7. Rindi G, Azzoni C, Rosa SL, Klersy C, Paolotti D, Rappel S, et al. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology. 1999;116(3):532–42.

    Article  CAS  PubMed  Google Scholar 

  8. Campana D, Nori F, Pezzilli R, Piscitelli L, Santini D, Brocchi E, et al. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocr Relat Cancer. 2008;15(1):337–42.

    Article  CAS  PubMed  Google Scholar 

  9. Murugesan SV, Steele IA, Dimaline R, Poston GJ, Shrotri M, Campbell F, et al. Correlation between a short-term intravenous octreotide suppression test and response to antrectomy in patients with type-1 gastric neuroendocrine tumours. Eur J Gastroenterol Hepatol. 2013;25(4):474–81.

    Article  CAS  PubMed  Google Scholar 

  10. Moore AR, Boyce M, Steele IA, Campbell F, Varro A, Pritchard DM. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of Type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis. PLoS One. 2013;8(10):e76462.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Moore AR, Varro A, Pritchard DM. Zollinger-Ellison syndrome. Gastrointest Nurs. 2012;10(5):44–9.

    Article  Google Scholar 

  12. Jensen RT, Niederle B, Mitry E, Ramage JK, Steinmüller T, Lewington V, et al. Gastrinoma (duodenal and pancreatic) ENETS guidelines. Neuroendocrinology. 2006;84(3):173–82.

    Article  CAS  PubMed  Google Scholar 

  13. Delle Fave G, Kwekkeboom DJ, Van Cutsem E, Rindi G, Kos-Kudla B, Knigge U, et al. ENETS consensus guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology. 2012;95(2):74–87.

    Article  CAS  PubMed  Google Scholar 

  14. Sato Y, Hashimoto S, Mizuno K, Takeuchi M, Terai S. Management of gastric and duodenal neuroendocrine tumors. World J Gastroenterol. 2016;22(30):6817–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Jann H, Roll S, Couvelard A, Hentic O, Pavel M, Müller-Nordhorn J, et al. Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer. 2011;117(15):3332–41.

    Article  PubMed  Google Scholar 

  16. Pape UF, Perren A, Niederle B, Gross D, Gress T, Costa F, et al. ENETS consensus guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas—abstract. Neuroendocrinology. 2012;95(2):135–56.

    Article  CAS  PubMed  Google Scholar 

  17. Pape U-F, Niederle B, Costa F, Gross D, Kelestimur F, Kianmanesh R, et al. ENETS consensus guidelines for neuroendocrine neoplasms of the appendix (excluding goblet cell carcinomas). Neuroendocrinology. 2016;103(2):144–52.

    Article  CAS  PubMed  Google Scholar 

  18. Jung YS, Yun KE, Chang Y, Ryu S, Park JH, Kim HJ, et al. Risk factors associated with rectal neuroendocrine tumors: a cross-sectional study. Cancer Epidemiol Prev Biomark. 2014;23(7):1406–13.

    Article  CAS  Google Scholar 

  19. Ramage JK, Herder WWD, Fave GD, Ferolla P, Ferone D, Ito T, et al. ENETS consensus guidelines update for colorectal neuroendocrine neoplasms. Neuroendocrinology. 2016;103(2):139–43.

    Article  CAS  PubMed  Google Scholar 

  20. Shen C, Yin Y, Chen H, Tang S, Yin X, Zhou Z, et al. Neuroendocrine tumors of colon and rectum: validation of clinical and prognostic values of the World Health Organization 2010 grading classifications and European Neuroendocrine Tumor Society staging systems. Oncotarget. 2016;8(13):22123–34.

    PubMed Central  Google Scholar 

  21. Niina Y, Fujimori N, Nakamura T, Igarashi H, Oono T, Nakamura K, et al. The current strategy for managing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1. Gut Liver. 2012;6(3):287–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990–3011.

    Article  CAS  PubMed  Google Scholar 

  23. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Consensus: guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86(12):5658–71.

    Article  CAS  PubMed  Google Scholar 

  24. Sharma J, Duque M, Saif MW. Emerging therapies and latest development in the treatment of unresectable pancreatic neuroendocrine tumors: an update for clinicians. Ther Adv Gastroenterol. 2013;6(6):474–90.

    Article  Google Scholar 

  25. McKenna LR, Edil BH. Update on pancreatic neuroendocrine tumors. Gland Surg. 2014;3(4):258–75.

    PubMed  PubMed Central  Google Scholar 

  26. Wilcox CM, Seay T, Arcury JT, Mohnen J, Hirschowitz BI. Zollinger–Ellison syndrome: presentation, response to therapy, and outcome. Dig Liver Dis. 2011;43(6):439–43.

    Article  PubMed  Google Scholar 

  27. Boyce M, Dowen S, Turnbull G, van den Berg F, Zhao C-M, Chen D, et al. Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects. Br J Clin Pharmacol. 2015;79(5):744–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Kittah NE, Vella A. Management of endocrine disease: pathogenesis and management of hypoglycemia. Eur J Endocrinol. 2017;177(1):R37–47.

    Article  CAS  PubMed  Google Scholar 

  29. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.

    Article  PubMed  Google Scholar 

  30. Pavel M, O’Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103(2):172–85.

    Article  CAS  PubMed  Google Scholar 

  31. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197(1):29–37.

    Article  PubMed  Google Scholar 

  32. O’Toole D, Ducreux M, Bommelaer G, Wemeau JL, Bouché O, Catus F, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer. 2000;88(4):770–6.

    Article  PubMed  Google Scholar 

  33. Rinke A, Muller H-H, Schade-Brittinger C, Klose K-J, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide lar in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27(28):4656–63.

    Article  CAS  PubMed  Google Scholar 

  34. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–33.

    Article  PubMed  Google Scholar 

  35. Faiss S, Pape U-F, Böhmig M, Dörffel Y, Mansmann U, Golder W, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—The International Lanreotide and Interferon Alfa study group. J Clin Oncol. 2003;21(14):2689–96.

    Article  CAS  PubMed  Google Scholar 

  36. Arnold R, Rinke A, Klose K-J, Müller H-H, Wied M, Zamzow K, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol. 2005;3(8):761–71.

    Article  CAS  PubMed  Google Scholar 

  37. Pavel M, Hörsch D, Caplin M, Ramage J, Seufferlein T, Valle J, et al. Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. J Clin Endocrinol Metab. 2015;100(4):1511–9.

    Article  CAS  PubMed  Google Scholar 

  38. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005–12.

    Article  CAS  PubMed  Google Scholar 

  39. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet Lond Engl. 2016;387(10022):968–77.

    Article  CAS  Google Scholar 

  41. Faivre S, Sablin M-P, Dreyer C, Raymond E. Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors. Endocrinol Metab Clin N Am. 2010;39(4):811–26.

    Article  CAS  Google Scholar 

  42. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Cives M, Strosberg J. Radionuclide therapy for neuroendocrine tumors. Curr Oncol Rep. 2017;19(2):9.

    Article  PubMed  Google Scholar 

  44. Alexandraki KI, Karapanagioti A, Karoumpalis I, Boutzios G, Kaltsas GA. Advances and current concepts in the medical management of gastroenteropancreatic neuroendocrine neoplasms. Biomed Res Int. 2017;2017:9856140.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000;190(4):432–45.

    Article  CAS  PubMed  Google Scholar 

  46. Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg. 1998;187(1):88–92. discussion-3

    Article  CAS  PubMed  Google Scholar 

  47. Elias D, Lasser P, Ducreux M, Duvillard P, Ouellet JF, Dromain C, et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery. 2003;133(4):375–82.

    Article  PubMed  Google Scholar 

  48. Kianmanesh R, O'Toole D, Sauvanet A, Ruszniewski P, Belghiti J. Surgical treatment of gastric, enteric pancreatic endocrine tumors. Part 2. Treatment of hepatic metastases. J Chir (Paris). 2005;142(4):208–19.

    Article  CAS  Google Scholar 

  49. Glazer ES, Tseng JF, Al-Refaie W, Solorzano CC, Liu P, Willborn KA, et al. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford). 2010;12(6):427–33.

    Article  Google Scholar 

  50. Alvarez FA, Ardiles V, de Santibanes M, Pekolj J, de Santibanes E. Associating liver partition and portal vein ligation for staged hepatectomy offers high oncological feasibility with adequate patient safety: a prospective study at a single center. Ann Surg. 2015;261(4):723–32.

    Article  PubMed  Google Scholar 

  51. Grozinsky-Glasberg S, Kaltsas G, Kaltsatou M, Lev-Cohain N, Klimov A, Vergadis V, et al. Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice. Endocrine. 2018;60(3):499–509.

    Article  CAS  PubMed  Google Scholar 

  52. Ahlman H, Wangberg B, Jansson S, Friman S, Olausson M, Tylen U, et al. Interventional treatment of gastrointestinal neuroendocrine tumours. Digestion. 2000;62(Suppl 1):59–68.

    Article  PubMed  Google Scholar 

  53. Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am. 2003;12(1):231–42.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Liverpool Regional Neuroendocrine Tumour Service, Royal Liverpool University Hospital, Liverpool, UK

    Andrew R. Moore

  2. Department of Hepatobiliary and Pancreatic Surgery, Royal Liverpool University Hospital, Liverpool, UK

    Vincent S. Yip

  3. Department of Hepatobiliary and Pancreatic Surgery, Royal London Hospital, London, UK

    Vincent S. Yip

Authors
  1. Andrew R. Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vincent S. Yip
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vincent S. Yip .

Editor information

Editors and Affiliations

  1. Royal Liverpool University Hospital, Liverpool, Merseyside, UK

    Tim Cross

  2. University of Liverpool, Liverpool Early Drug Development Unit, Liverpool, UK

    Daniel H. Palmer

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Moore, A.R., Yip, V.S. (2019). Treatment of Neuroendocrine Tumour Disease. In: Cross, T., Palmer, D. (eds) Liver Cancers. Springer, Cham. https://doi.org/10.1007/978-3-319-92216-4_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-92216-4_20

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-92215-7

  • Online ISBN: 978-3-319-92216-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation